Lorlatinib

證據等級: L5

預測適應症: 10 個

Lorlatinib: From ALK-Positive Non-Small Cell Lung Cancer to Fibromatosis, Gingival

One-Sentence Summary

Lorlatinib is a third-generation ALK/ROS1 tyrosine kinase inhibitor whose established use is ALK-positive non-small cell lung cancer (NSCLC), per the drug-safety literature included in this evidence pack. The TxGNN model's top-ranked prediction for this candidate is Fibromatosis, Gingival, but this association is currently supported by 0 clinical trials and 0 publications, and the accompanying rationale flags it as likely model noise rather than a genuine mechanistic signal.

Quick Overview

Item	Content
Original Indication	ALK-positive Non-Small Cell Lung Cancer (NSCLC) — derived from literature context (e.g. PMID 38554546); not confirmed via Finland regulatory filing, as none exists
Predicted New Indication	Fibromatosis, Gingival
TxGNN Prediction Score	99.81%
Evidence Level	L5
Finland Market Status	未上市 (Not marketed)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (DrugBank MOA field is a data gap for this record). Based on the literature retrieved for this candidate's broader evidence set, lorlatinib is a brain-penetrant, third-generation ALK/ROS1 tyrosine kinase inhibitor whose established clinical activity is in ALK-rearranged malignancies, principally NSCLC.

Gingival fibromatosis, however, is a hereditary connective-tissue overgrowth condition most commonly linked to genes such as SOS1 and REST. There is no known involvement of the ALK or ROS1 signalling pathways in its pathophysiology, and no oncogenic driver relationship connects it to lorlatinib's target profile.

The repurposing rationale attached to this candidate explicitly states that the prediction has no supporting clinical trial or publication evidence and describes it as arising "purely from model prediction noise" (原文：純屬模型預測雜訊), with no plausible mechanistic bridge between lorlatinib's pharmacology and this disease. This candidate should therefore not be interpreted as a credible repurposing signal in its current form.

Note: this evidence pack ranked 10 candidate indications for lorlatinib; this report covers the top-ranked one by TxGNN score. Two other candidates in the same batch (lung hilum carcinoma; lung germ cell tumor) reached evidence level L3 with literature support, though both were also flagged for disease-label/ontology mapping concerns and would warrant separate evaluation.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Finland Market Information

Lorlatinib is not currently marketed in Finland (market status: 未上市). No marketing authorizations are on file for this product.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (ALK/ROS1 tyrosine kinase inhibitor; non-cytotoxic mechanism)
Myelosuppression Risk	Low — not a conventional cytotoxic agent; myelosuppression is not a prominent finding in the available literature
Emetogenicity Classification	Low, consistent with other ALK inhibitors
Monitoring Items	Lipid panel (hypercholesterolemia/hypertriglyceridemia reported in case literature), liver function, weight/BMI, mood and cognitive status, pulmonary symptoms (rare ARDS reported in case literature)
Handling Protection	Oral targeted therapy; standard institutional oral-oncolytic handling precautions apply. No cytotoxic (hazardous drug) handling classification confirmed — please refer to the package insert for definitive guidance

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: This is TxGNN's highest-scoring prediction for lorlatinib, but it has zero clinical trial or literature support, and the disease's known genetic etiology (SOS1/REST-related) shows no mechanistic link to lorlatinib's ALK/ROS1 target. The evidence pack itself flags this as likely prediction noise, so it does not meet the threshold to proceed.

To proceed, the following is needed:

Confirmed original indication and mechanism-of-action data from DrugBank (currently a High-severity data gap, DG001)
TFDA-equivalent (Finland) package insert warnings/contraindications (currently a Blocking data gap)
Independent mechanistic or preclinical evidence linking ALK/ROS1 inhibition to gingival fibromatosis before any further investment
If repurposing research continues on this drug, prioritize re-evaluating the higher-evidence candidates in the same batch (e.g., lung hilum carcinoma, lung germ cell tumor) after resolving their noted disease-ontology mapping issues, rather than this candidate
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.